SEC Form 4 · accession 0001140361-26-025950
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Weiguo Ye
Officer — Chief Operating Officer
Period of report
Jun 9, 2026
Accepted (ET)
Jun 22, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 9, 2026 | M | 3,000 | $0.75 | A | 703,000 | D | |
| Common Stock | Jun 9, 2026 | S | 3,000 | $6.15 | D | 700,000 | D | |
| Common Stock | Jun 10, 2026 | M | 5,000 | $0.75 | A | 705,000 | D | |
| Common StockF1 | Jun 10, 2026 | S | 5,000 | $6.24 | D | 700,000 | D | |
| Common Stock | Jun 18, 2026 | M | 3,000 | $0.75 | A | 703,000 | D | |
| Common Stock | Jun 18, 2026 | S | 3,000 | $6.35 | D | 700,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.75 | Jun 9, 2026 | M | 3,000 | D | — | Oct 31, 2030 | Common Stock | 3,000 | 835,701 | D |
| Stock Option (Right to Buy)F2 | $0.75 | Jun 10, 2026 | M | 5,000 | D | — | Oct 31, 2030 | Common Stock | 5,000 | 830,701 | D |
| Stock Option (Right to Buy)F2 | $0.75 | Jun 18, 2026 | M | 3,000 | D | — | Oct 31, 2030 | Common Stock | 3,000 | 827,701 | D |
Explanation of responses
- F1The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F2These options are vested in full.